Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London
NeoPhore, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic […]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced […]
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx announced today that they have entered into a collaboration agreement to jointly […]
Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR)
Sapience Therapeutics, a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics […]
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]
WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary […]
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
M2GEN Rebrands to Aster Insights
M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomic data to accelerate medical […]
Function Oncology Launches to Transform the Future of Targeted Cancer Treatment with CRISPR
Function Oncology, a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to transform […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more